Page 42 - Amgen News Today

Shareholders grill executives, as questions abound over Boeing's way forward.

BioPharma

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

The S&P 500's 27.5% rise for the last 12 months easily tops the 19.7% gain for the Dow.

First National Advisers LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 110.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 9,454 shares of the medical research company’s stock after buying an additional 4,965 shares during the period. First National Advisers LLC’s holdings in Amgen were worth $2,723,000 […]

First National Advisers LLC grew its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 110.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,454 shares of the medical research company’s stock after buying an additional 4,965 shares during the quarter. First National […]

Through its long history, the Dow Jones Industrial Average has offered a way for people to get a quick read on how Wall Street is doing.

Great Lakes Advisors LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 331,137 shares of the medical research company’s stock after selling 75,351 shares during the quarter. Amgen accounts for […]

The agency cleared the drug, called Imdelltra, as a second or later-line treatment for adults with advanced small-cell lung cancer.

-The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgens tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small...